TVTX vs ZBH
Travere Therapeutics, Inc. vs Zimmer Biomet — AI-powered side-by-side comparison
TVTX
Travere Therapeutics, Inc.
62
Buy
VS
| Metric | TVTX | ZBH |
|---|
| AI Score |
62
|
69
|
| Price |
$60.25
|
$97.22
|
| P/E Ratio |
-133.80×
|
23.54×
|
| ROE |
-22.2%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
94.4%
|
69.9%
|
| Debt / Equity |
25.16×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
59.0
|
63.1
|
| Beta |
1.042
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for TVTX versus ZBH.
ZBH leads by 7 points.
ZBH scores 69/100 (Buy) versus TVTX at 62/100 (Buy).
TVTX Committee View
75% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 17.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Bollinger bandwidth of 17.2% signals elevated volatility — Risk
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical